PDT Partners LLC Sells 212,406 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

PDT Partners LLC reduced its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 93.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,814 shares of the company’s stock after selling 212,406 shares during the quarter. PDT Partners LLC’s holdings in Intellia Therapeutics were worth $304,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Blue Trust Inc. lifted its holdings in Intellia Therapeutics by 1,664.3% in the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after acquiring an additional 1,398 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in Intellia Therapeutics by 763.5% in the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after acquiring an additional 1,550 shares during the period. Eastern Bank bought a new position in Intellia Therapeutics in the third quarter valued at about $41,000. Values First Advisors Inc. bought a new position in Intellia Therapeutics in the third quarter valued at about $54,000. Finally, First Horizon Advisors Inc. lifted its holdings in Intellia Therapeutics by 22.1% in the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock valued at $58,000 after acquiring an additional 472 shares during the period. 88.77% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. JPMorgan Chase & Co. lowered their target price on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. Chardan Capital raised their price objective on Intellia Therapeutics from $88.00 to $91.00 and gave the stock a “buy” rating in a research note on Monday, November 18th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday, November 19th. Evercore ISI raised Intellia Therapeutics to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $54.00 price objective on shares of Intellia Therapeutics in a research note on Thursday, September 19th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Intellia Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $54.94.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the transaction, the chief accounting officer now owns 47,012 shares in the company, valued at $893,698.12. This trade represents a 4.10 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 3.20% of the stock is currently owned by company insiders.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $14.65 on Wednesday. The stock has a market capitalization of $1.49 billion, a PE ratio of -2.69 and a beta of 1.76. The business has a 50 day simple moving average of $17.00 and a two-hundred day simple moving average of $21.19. Intellia Therapeutics, Inc. has a 1-year low of $12.82 and a 1-year high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to analysts’ expectations of $8.28 million. The business’s quarterly revenue was down 24.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.38) EPS. On average, analysts anticipate that Intellia Therapeutics, Inc. will post -5.12 EPS for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.